Nestle Health signed a $1.9 billion microbiome deal with Seres; Thermo Fisher paid $1.3 billion for fellow life sciences company Affymetrix. Biopharma and device financing totaled $2.9 billion and $254 million, respectively.
Strategic Transactions
Exhibit 4
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
